EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ribociclib plus letrozole alters the blood immune profile in older patients with HR+/HER2- metastatic breast cancer

Yentl Lambrechts, Sigrid Hatse, Cindy Kenis, Lore Decoster, Lore Decoster, Evandro de Azambuja, Patrick Neven, Claire Quaghebeur, Frank Cornelis, Didier Verhoeven, Annelore Barbeaux, Jeroen Mebis und 9 weitere

Ageing and Cancer Research & Treatment · 2024

DOI: 10.70401/acrt.2024.84 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ageing and Cancer Research & Treatment, 2024. Verfasst von Yentl Lambrechts und 20 weiteren Autor:innen. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The combination of CDK4/6 inhibitors and endocrine therapy (ET) is a standard first-line therapy for hormone receptor positive (HR+)/HER2- metastatic breast cancer (mBC). Preliminary data suggest that CDK4/6 inhibitors can alter the host immune function and stimulate tumor cell-directed immunity. However, clinical data are scarce, and no data exist about the impact of age and frailty on this phenomenon. Materials and Methods: This biomarker substudy of the RibOB trial evaluated the impact of ribociclib and letrozole on circulating immune cell subsets and protein markers in older (≥ 70 years) patients with HR+/HER2-mBC. Peripheral blood mononuclear cell subtyping and analysis of plasma immune response and checkpoint markers were performed using flow cytometry at baseline and after three months of ribociclib + ET. Frailty status was assessed at baseline using G8 score.

Results

20 patients (median age: 76 years, range: 70 - 87 years), 8 considered fit (G8 > 14), and 12 frail (G8 ≤ 14), were included. After three months of treatment, the immune subset composition showed significant increases in naïve B-, T-regulatory (Tregs), and CD4+ T-cells, while memory B-cells and Tregs were significantly decreased. In addition, consistent upregulation was seen in costimulatory receptors CD27 and CD28. Plasma immune checkpoint markers B7.2 (CD86) and PD-1 were significantly decreased. The immune subset profiles of fit versus frail persons showed no statistically significant difference.

Conclusions

The study shows that the combination of ribociclib and ET modulates the immune system in older patients, potentially reversing the age-related immunosenescence process by increasing naïve T-cell and B-cell populations and decreasing memory populations. Clinical trial registration number: NCT03956654.

Zitieren

APA

Lambrechts, Y., Hatse, S., Kenis, C., Decoster, L., Decoster, L., Azambuja, E. D., Neven, P., Quaghebeur, C., Cornelis, F., Verhoeven, D., Barbeaux, A., Mebis, J., Dievel, J. V., Verschaeve, V., Duck, L., Cuypere, E. D., Floris, G., Desmedt, C., Laenen, A., …, & Wildiers, H. (2024). Ribociclib plus letrozole alters the blood immune profile in older patients with HR+/HER2- metastatic breast cancer. Ageing and Cancer Research & Treatment. https://doi.org/10.70401/acrt.2024.84

Vancouver

Lambrechts Y, Hatse S, Kenis C, Decoster L, Decoster L, Azambuja ED, et al. Ribociclib plus letrozole alters the blood immune profile in older patients with HR+/HER2- metastatic breast cancer. Ageing and Cancer Research & Treatment. 2024. doi:10.70401/acrt.2024.84

BibTeX
@article{Lambrechts2024,
  author = {Lambrechts, Yentl and Hatse, Sigrid and Kenis, Cindy and Decoster, Lore and Decoster, Lore and Azambuja, Evandro de and Neven, Patrick and Quaghebeur, Claire and Cornelis, Frank and Verhoeven, Didier and Barbeaux, Annelore and Mebis, Jeroen and Dievel, Julie Van and Verschaeve, Vincent and Duck, Lionel and Cuypere, Eveline De and Floris, Giuseppe and Desmedt, Christine and Laenen, Annouschka and Pondé, Noam and Wildiers, Hans},
  title = {Ribociclib plus letrozole alters the blood immune profile in older patients with HR+/HER2- metastatic breast cancer},
  journal = {Ageing and Cancer Research & Treatment},
  year = {2024},
  doi = {10.70401/acrt.2024.84}
}
Kostenlos starten →